genomics

Kris Wood, PhD, and colleagues have discovered a potential new drug therapy for leukemia that's preparing to enter clinical trials.

DCI member and physician-scientist Sandeep Dave, MD, MS, has been named the Wellcome Clinical Distinguished Professor of Medicine.

Holly Dressman has been named director of Duke’s Sequencing and Genomic Technologies (SGT) Core Facility. Nicolas Devos, PhD, has stepped down from his role as SGT director.

Dukes receives two large grants totaling nearly $12 million from the National Human Genome Research Institute (NHGRI) as part of its new Impact of Genomic Variation on Function (IGVF) Consortium.

For most cancers, advances in genomics haven't changed cancer diagnosis and treatment very much. Sandeep Dave, MD, MS, envisions a way to change that.

Zhao Zhang, PhD, is one of 22 scholars (early-career junior faculty) nationwide this year to receive this 4-year, $300,000 grant award.

“I had always considered myself one of the healthiest people I knew ...”

After 32 years with the Duke Cancer Institute family, breast medical oncologist P. Kelly Marcom, MD, retired from clinical practice at the end of May.

DCI faculty Michaela Dinan, PhD, on the impact of the Oncotype DX test on HR+ breast cancer patients over 65, treatment disparities, & the latest therapies.

The Donald Lab, led by Bruce Donald, PhD, is designing proteins for a historically undruggable protein that’s implicated in difficult-to-treat cancers like pancreatic cancer.

Funding from the Elsa U. Pardee Foundation will allow investigator to study muscle regeneration and cancer.

Scott Soderling, PhD, has founded a Duke spinout company based on a technology developed in his lab that uses the genome-editing tool CRISPR.

Medical oncologist John Strickler, MD, and his patient Tom Vibert, a stage 4 colon cancer survivor, talk about the importance of biomarker testing.

Duke University School of Medicine podcast "HeadScratchers" features Kelly Marcom, MD.

For some patients, targeted therapy is their best shot. The Molecular Tumor Board at DCI is matching more and more patients to approved therapies and clinical trials.

DCI was invited to join the elite international AACR Project GENIE consortium, whose registry contains clinical-grade cancer genomic sequencing data from nearly 71,000 patients & 80 major cancer types.

The Center for Advanced Genomic Technologies will seek potential therapies for diseases from cancer to schizophrenia.

Ginsburg’s areas of focus include the study of novel paradigms for developing and translating genomic information into medical practice.